Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of treatment or control group before and after propensity score adjustment

From: Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis

 Treatment group (n = 232)UnadjustedAdjusted including baseline SUAAdjusted including preoperative SUA
Control group (n = 604)Absolute standardized differenceControl groupAbsolute standardized differenceControl groupAbsolute standardized difference
Age (years), mean ± SD65.8 ± 14.061.4 ± 15.20.3364.8 ± 13.70.06966.4 ± 13.50.042
Male sex, %91.887.90.1389.40.08290.10.059
eGFR (ml/min/1.73 m2), mean ± SD82.5 ± 50.281.0 ± 36.30.0380.8 ± 41.90.03780.6 ± 28.40.036
Baseline (Pre-treatment) SUA (mg/dL), mean ± SD9.19 ± 1.577.76 ± 0.881.128.92 ± 1.110.198  
Preoperative SUA (mg/dL), mean ± SD5.47 ± 2.281.33  5.78 ± 1.610.157
Urinary lithiasis, %3.41.50.132.80.043.60.01
Hypertension, %65.539.40.5458.00.1661.70.08
Ischemic heart disease, %34.518.90.3632.10.0535.80.03
Heart failure, %35.819.40.3730.10.1231.90.08
Diabetes mellitus, %37.925.00.2835.50.0536.20.04
Cancer, %63.451.80.2362.30.0255.30.17
Liver disease, %37.118.20.4332.60.1033.30.08
Diuretics, %19.815.70.1117.10.0717.70.05
ACE inhibitors, %9.94.40.219.20.028.10.06
ARBs, %18.59.80.2517.70.0217.90.02
Antibiotics, %37.131.50.1234.30.0633.80.07
NSAIDs, %57.349.50.1655.10.0450.60.14
Anticancer drugs, %1.73.00.081.50.071.20.04
Contrast media, %9.18.80.018.90.019.00.003
Surgeries, %, mean [range]0.8 [0.4–4.3]0.8 [0.2–7.0]0.06 [0–0.301]0.8 [0.1–4.6]0.04 [0–0.188]0.8 [0.1–4.5]0.04 [0–0.175]
  1. SD standard deviation, eGFR estimated glomerular filtration rates, SUA serum uric acid, ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, NSAIDs nonsteroidal anti-inflammatory drugs